SynthesisAdvances in rheumatology (London, England)2026
Blood levels of brain-derived neurotrophic factor (BDNF) in psoriasis: a systematic review and meta-analysis.
Synthesis in Advances in rheumatology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPsoriasis is a chronic inflammatory skin condition affecting 0.1–1.5% of the global population. The condition is linked to impaired quality of life and increased morbidity. Brain-derived neurotrophic factor (BDNF) is a neurotrophin associated with neuronal development and synaptic plasticity; its dysregulation has been implicated in the pathogenesis of psoriasis. This study systematically reviews and analyzes the relationship between BDNF levels and psoriasis.
methodsA systematic review and meta-analysis were conducted by the PRISMA 2020 guidelines. Comprehensive searches were performed on MEDLINE, Scopus, EMBASE, and Web of Science databases up to January 19th, 2024. Eligible studies measured circulating BDNF levels in psoriasis patients and compared them with healthy controls. The Newcastle-Ottawa Scale (NOS) was used to assess the quality of included studies. Meta-analyses were performed using standardized mean differences (SMD) with either fixed or random-effects models based on heterogeneity measures.
resultsSix studies met the inclusion criteria, with data from 2006 to 2020. Meta-analysis revealed a significant reduction in BDNF levels in psoriasis patients compared to healthy controls (SMD −0.577, 95% CI [−0.915, −0.239], p = 0.0008). Heterogeneity was substantial (I2 = 70.2%). Sensitivity analysis identified one study as a major contributor to heterogeneity. No significant factors contributing to heterogeneity were identified through meta-regression.
conclusionThis study found a significant reduction in BDNF levels in psoriasis patients, suggesting a potential link between BDNF dysregulation and the pathophysiology of psoriasis. Understanding the role of BDNF in these conditions may inform future research and therapeutic strategies for patients suffering from both. Further research is needed to explore the relationship and the mechanisms underlying the associations of psoriasis and any probable related comorbidities, such as depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.